Trials / Completed
CompletedNCT00426998
Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD
A 24 Month Randomized, Double-Masked, Single Center, Phase II Study Comparing Photodynamic Therapy With Verteporfin (Visudyne)Plus Two Different Timing Regimens of Intravitreal Bevacizumab (Avastin) Given 1 Week Prior to or 1 Week Following Photodynamic Therapy in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- Retinal Consultants Medical Group · Academic / Other
- Sex
- All
- Age
- 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to compare different timing therapies of Verteporfin with Bevacizumab to treat choroidal neovascularization (CNV) due to age-related macular degeneration (AMD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Verteporfin | |
| DRUG | Bevacizumab |
Timeline
- Start date
- 2006-04-01
- First posted
- 2007-01-26
- Last updated
- 2007-01-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00426998. Inclusion in this directory is not an endorsement.